Share on StockTwits

Shares of Masimo (NASDAQ:MASI) have received a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the stock, American Banking News.com reports. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $26.67.

Masimo (NASDAQ:MASI) opened at 21.94 on Monday. Masimo has a 52-week low of $19.30 and a 52-week high of $32.20. The stock’s 50-day moving average is $23.59 and its 200-day moving average is $25.24. The company has a market cap of $1.202 billion and a price-to-earnings ratio of 20.27.

Masimo (NASDAQ:MASI) last released its earnings data on Thursday, August 7th. The company reported $0.24 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.29 by $0.05. The company had revenue of $140.92 million for the quarter, compared to the consensus estimate of $145.76 million. During the same quarter last year, the company posted $0.30 earnings per share. Masimo’s revenue was up 2.5% compared to the same quarter last year. Analysts expect that Masimo will post $1.25 EPS for the current fiscal year.

A number of analysts have recently weighed in on MASI shares. Analysts at Zacks reiterated a “neutral” rating on shares of Masimo in a research note on Monday, August 11th. They now have a $23.00 price target on the stock. Separately, analysts at Citigroup Inc. reiterated a “neutral” rating on shares of Masimo in a research note on Monday, August 11th. They now have a $27.00 price target on the stock, down previously from $29.00. Finally, analysts at BMO Capital Markets cut their price target on shares of Masimo from $26.00 to $24.00 in a research note on Friday, August 8th.

Masimo Corporation, is a global medical technology company that develops, manufactures, and markets noninvasive patient monitoring products.

Receive News & Ratings for Masimo Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Co and related companies with Analyst Ratings Network's FREE daily email newsletter.